08:00 , Nov 4, 2002 |  BC Week In Review  |  Clinical News

LJP 1082: Phase I/II

Preliminary results from a placebo-controlled U.S. Phase I/II trial showed that a single administration of LJP 1082 was well tolerated at 5 dose levels in 20 patients. Those receiving higher doses of LJP 1082 had...
08:00 , Nov 12, 2001 |  BC Week In Review  |  Clinical News

LJP 1082: Began Phase I/II trial

La Jolla Pharmaceutical Co. (LJPC), San Diego, Calif.   Product: LJP 1082   Business: Autoimmune/Inflammation   Therapeutic category: Immune modulation   Target: Antibodies against beta 2 glycoprotein   Description: Toleragen that binds to antibodies against beta 2 glycoprotein...
07:00 , Sep 17, 2001 |  BC Week In Review  |  Clinical News

LJP 1082: Began Phase I/II trial

La Jolla Pharmaceutical Co. (LJPC), San Diego, Calif.   Product: LJP 1082   Business: Autoimmune/Inflammation   Therapeutic category: Immune modulation   Target: Antibodies against beta 2 glycoprotein   Description: Toleragen that binds to antibodies against beta 2 glycoprotein...
07:00 , Sep 11, 2001 |  BC Extra  |  Clinical News

LJPC to begin Phase I/II

La Jolla Pharmaceutical (LJPC) filed an IND with the FDA to start Phase I/II trials of LJP 1082 to treat antibody mediated thrombosis. LJP 1082 is a toleragen that binds to antibodies against beta 2...
07:00 , Aug 13, 2001 |  BC Week In Review  |  Company News

La Jolla Pharma other research news

LJPC said an analysis of serum samples from 106 APS patients published in Thrombosis and Haemostasis confirmed that a binding site recognized by anti-b2-GPI antibodies on platelets is responsible for the disorder. The company said...
07:00 , Sep 25, 2000 |  BC Week In Review  |  Clinical News

La Jolla Pharma preclinical data

LJPC said that in rats immunized with beta 2 GP1, a protein involved in blood clot formation, LJP 1082 treatment reduced antibodies against the antigen and B cells producing those antibodies by 90 percent. The...